Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BITRF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.22
N/A
-0.00
vs -0.00
Q2.22
N/A
-0.00
vs -0.00
Q3.22
N/A
-0.00
vs -0.00
Q4.22
N/A
-0.00
vs -0.00
Q1.23
N/A
-0.00
vs -0.00
Q2.23
N/A
-0.00
vs -0.00
Q3.23
N/A
-0.00
vs -0.00
Q4.23
N/A
-0.00
vs -0.00
Q1.24
N/A
-0.00
vs -0.00
Q2.24
N/A
-0.00
vs -0.00
Sales Growth
YoY
Current
Estimates
Q1.22
+10%
779.3K vs 706K
Q2.22
+10%
779.3K vs 706K
Q3.22
NA
715.6K vs NA
Q4.22
NA
715.6K vs NA
Q1.23
-100%
NA vs 779.3K
Q2.23
-100%
NA vs 779.3K
Q3.23
+15%
822.6K vs 715.6K
Q4.23
+15%
822.6K vs 715.6K
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Return on Equity
QoQ
Q3.22
NA
NA
vs NA
Q4.22
-14%
-0.14
vs -0.77
Q1.23
NA
NA
vs NA
Q2.23
-85%
-0.85
vs -0.14
Q3.23
NA
NA
vs NA
Q4.23
-71%
-0.71
vs -0.85
Q1.24
NA
NA
vs NA
Q2.24
+866%
8.66
vs -0.71
Q3.24
NA
NA
vs NA
Q4.24
+152%
1.52
vs 8.66
Institutionnal Ownership
N/A
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
NA
NA
vs NA
NA
Q1.25
NA
NA
vs NA
NA
Q2.25
NA
NA
vs NA
NA
Q3.25
NA
NA
vs NA
NA
Relative Strength
BITRF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
OTC
Unprofitable
Unprofitable
Pre-market 0.01$
0.00 (-0.38%)
Relative Strenght
Volume Buzz
1523%
Earning Acce
No
Dist 52w H.
74%Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available